Phase I Study of Individualized Neoantigen Peptides in the Treatment of EGFR Mutant Non-small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
Neoantigen vaccine is a new field of research in tumor immunotherapy, and some studies have
been conducted with success on Melanoma and glioblastoma. Nearly 80% of lung cancers are
diagnosed in an advanced stage (IIIB, and IV) and EGFR mutant non-small cell lung cancer will
be resistant after targeted drug treatment. Neoantigen vaccine is a new treatment method for
lung cancer, especially for patients with drug resistance.
Phase:
Phase 1
Details
Lead Sponsor:
Sun Yat-sen University
Collaborator:
Tianjin Hengjia Biotechnology Development co., LTD